<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04468204</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00100980</org_study_id>
    <nct_id>NCT04468204</nct_id>
  </id_info>
  <brief_title>Use of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI)</brief_title>
  <official_title>Use of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory (URI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to test the safety, efficacy and potential mechanism of action of the
      SinuSonic device on adults with upper respiratory infection (URI). SinuSonic is a medical
      device that utilizes sound and pressure combined with normal breathing. The study will have 2
      aims. Aim 1 willdetermine if Sinusonic decreases the number of URIs experienced during an 8
      week fall URI season. Subjects will use an active device (positive expiratory pressure and
      128 Hz) or a sham device (no positive expiratory pressure and 1,000 Hz) for 1 min tid for 8
      weeks. Aim 2 will determine if Sinusonic decreases the severity and duration of community
      acquired viral URIs. Subjects will use active or sham device as above.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Symptoms Score (TSS)</measure>
    <time_frame>60 Days</time_frame>
    <description>The Total Symptom Score (TSS) was based on the severity of each of upper respiratory infection (URI) symptom.
The TSS includes 9 symptoms: Lost sense of smell/taste, sneezing, runny nose or thick nasal discharge, nasal obstruction or congestion, sore throat, cough headache, maliase, and chilliness.
The severity of URI symptoms was scored on a symptom severity scale (0 = not at all; 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms)
Minimum score=0; maximum score=27.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Upper Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>SinuSonic Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SinuSonic device used for 1 min three times a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham SinuSonic device used for 1 min three times a day for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SinuSonic Device</intervention_name>
    <description>A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.</description>
    <arm_group_label>SinuSonic Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham SinuSonic Device</intervention_name>
    <description>Sham positive expiratory pressure intervention using the SinuSonic Device.</description>
    <arm_group_label>Sham</arm_group_label>
    <other_name>Sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 years or older with no transient symptoms of any URI or allergies at
             baseline.

        Exclusion Criteria:

          -  Any transient ENT condition that may impact upper airway to include acute sinusitis or
             otitis.

          -  Any upper respiratory illness within last 2 weeks

          -  TSS will be measured at baseline as described above and must be &lt;9 for inclusion
             (Eccles etal).

          -  Topical decongestant use in last week

          -  Current nasal crusting or history of ulceration or perforation

          -  History of severe nose bleeding within last 3 months

          -  Known pregnancy

          -  Immunosuppressed condition or on immune modulating medications such as prednisone or
             chemotherapy

          -  Allergic sensitivity to silicone or any other component of device

          -  Inability to read and understand English

          -  Inability to perform treatment due to underlying medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shaun A. Nguyen</last_name>
    <phone>8437921356</phone>
    <email>nguyensh@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ted A. Meyer</last_name>
    <phone>843-876-0112</phone>
    <email>meyerta@musc.edu</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Shaun A. Nguyen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not Applicable. The investigators plan to publish this study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

